Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1963 2
1964 3
1966 4
1967 2
1968 4
1969 3
1970 7
1971 1
1972 5
1973 14
1974 9
1975 7
1976 4
1977 10
1978 8
1979 5
1980 8
1981 7
1982 12
1983 6
1984 12
1985 9
1986 8
1987 7
1988 9
1989 12
1990 20
1991 14
1992 27
1993 18
1994 28
1995 29
1996 44
1997 50
1998 41
1999 31
2000 31
2001 28
2002 26
2003 28
2004 23
2005 24
2006 34
2007 42
2008 33
2009 24
2010 26
2011 27
2012 34
2013 51
2014 36
2015 66
2016 65
2017 52
2018 63
2019 45
2020 46
2021 71
2022 40
Text availability
Article attribute
Article type
Publication date

Search Results

1,300 results
Results by year
Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan). Hiraoka A, et al. Among authors: okubo t. Cancer Rep (Hoboken). 2022 Feb;5(2):e1464. doi: 10.1002/cnr2.1464. Epub 2021 Jun 11. Cancer Rep (Hoboken). 2022. PMID: 34114752 Free PMC article.
First-in-human clinical trial of transplantation of iPSC-derived NS/PCs in subacute complete spinal cord injury: Study protocol.
Sugai K, Sumida M, Shofuda T, Yamaguchi R, Tamura T, Kohzuki T, Abe T, Shibata R, Kamata Y, Ito S, Okubo T, Tsuji O, Nori S, Nagoshi N, Yamanaka S, Kawamata S, Kanemura Y, Nakamura M, Okano H. Sugai K, et al. Among authors: okubo t. Regen Ther. 2021 Sep 7;18:321-333. doi: 10.1016/j.reth.2021.08.005. eCollection 2021 Dec. Regen Ther. 2021. PMID: 34522725 Free PMC article.
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Aoki T, Tanaka T, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: okubo t. Sci Rep. 2021 Aug 17;11(1):16663. doi: 10.1038/s41598-021-96089-x. Sci Rep. 2021. PMID: 34404856 Free PMC article.
Generation of 3D lacrimal gland organoids from human pluripotent stem cells.
Hayashi R, Okubo T, Kudo Y, Ishikawa Y, Imaizumi T, Suzuki K, Shibata S, Katayama T, Park SJ, Young RD, Quantock AJ, Nishida K. Hayashi R, et al. Among authors: okubo t. Nature. 2022 May;605(7908):126-131. doi: 10.1038/s41586-022-04613-4. Epub 2022 Apr 20. Nature. 2022. PMID: 35444274
No more trial and error for zeolites.
Chaikittisilp W, Okubo T. Chaikittisilp W, et al. Among authors: okubo t. Science. 2021 Oct 15;374(6565):257-258. doi: 10.1126/science.abm0089. Epub 2021 Oct 14. Science. 2021. PMID: 34648342
Phase shift in skyrmion crystals.
Hayami S, Okubo T, Motome Y. Hayami S, et al. Among authors: okubo t. Nat Commun. 2021 Dec 1;12(1):6927. doi: 10.1038/s41467-021-27083-0. Nat Commun. 2021. PMID: 34853320 Free PMC article.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan. Hiraoka A, et al. Among authors: okubo t. Hepatol Res. 2022 Mar;52(3):308-316. doi: 10.1111/hepr.13734. Epub 2021 Dec 2. Hepatol Res. 2022. PMID: 34799975
1,300 results